At Sola, we develop innovative molecular diagnostics in the interest of patients and healthcare professionals, while establishing our solutions as an integral part of future standards of care.
With that in mind, we are very pleased to report that the WID®-easy Test has been included in the recommendations-supporting background text of the updated German S3 Guideline on Endometrial Cancer (v4.0, May 2026, AWMF 032-034OL).
Section 4.3 of the guideline (pages 67-68) cites four peer-reviewed validation studies and
- attributes the WID®-easy Test with a sensitivity of > 95 % and a negative predictive value of ≥ 99.7 % on the basis of the studies cited (Herzog et al., J Clin Oncol 2022; Evans et al., Lancet Oncol 2023; Illah et al., Int J Cancer 2024; Ken-Amoah et al., Int J Cancer 2025);
- describes a reduction of invasive workup from 19 to 2 D&C procedures per cancer detected versus transvaginal ultrasound alone (at a realistic prevalence of 3.4%); and
- indicates that the WID®-easy Test has the potential to improve diagnostic workup in women with peri-/postmenopausal bleeding by reducing the rate of invasive procedures.
To read the full text of the guidelines click here: https://www.leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom